⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 8, 2004British journal of rheumatologyOpen Access

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R))

View Full Paper

Ask AI

Bookmark

Share

Authors

GKGisela KobeltMoritz Klinik

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gisela Kobelt (2004) studied this question.

synapsesocial.com/papers/6a8a4a105c716ca1a5d4685f https://doi.org/10.1093/rheumatology/keh271

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

1The cost‐effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study2003 · 165 citations